ADMAADMA Biologics, Inc.

$4B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$134M+12.0% YoY

Gross Profit

$76M56.3% margin

Operating Income

$51M38.0% margin

Net Income

$36M27.1% margin

EPS (Diluted)

$0.15

QoQ Revenue Growth

+10.0%

Cash Flow

Operating Cash Flow

$13M

Free Cash Flow

-$1M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$569M

Total Liabilities

$138M

Stockholders' Equity

$431M

Cash & Equivalents

$61M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$134M	$120M	+12.0%
Gross Profit	$76M	$60M	+26.8%
Operating Income	$51M	$40M	+28.7%
Net Income	$36M	$36M	+1.4%

Geographic Segments

UNITED STATES

$134M100%

Non-US

$246,0000%

ADMA Q3 2025 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena